lobbying_activities: 2305873

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2305873	b0cbf4c6-e908-4d38-a3c4-217fc3800310	Q2	ELI LILLY AND COMPANY	13392	ELI LILLY AND COMPANY	2019	second_quarter	CSP	Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation	Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)		2330000	0	0	2019-07-16T16:38:08.143000-04:00